Compared to patients with DEK-NUP214 negative AML, patients with DEK-NUP214 positive AML had a lower complete remission (CR) (67% versus 79%, p = 0.04), lower OS (39% versus 57%, p = 0.03), and higher relapse rates (64% versus 42%, p = 0.04) [107]. The gene discussed is NUP214; the disease is acute myeloid leukemia.